SunTrust Reiterates Neutral Rating for Amedisys (AMED)
Amedisys (NASDAQ:AMED)‘s stock had its “neutral” rating restated by analysts at SunTrust in a research report issued to clients and investors on Thursday. They currently have a $23.00 target price on the stock, up from their previous target price of $18.00. SunTrust’s price target points to a potential upside of 13.97% from the stock’s previous close.
Shares of Amedisys (NASDAQ:AMED) traded up 0.10% during mid-day trading on Thursday, hitting $20.18. 1,031,441 shares of the company’s stock traded hands. Amedisys has a 1-year low of $11.77 and a 1-year high of $20.93. The stock has a 50-day moving average of $15.29 and a 200-day moving average of $14.98. The company’s market cap is $662.1 million.
Amedisys (NASDAQ:AMED) last released its earnings data on Wednesday, July 30th. The company reported $0.25 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.04 by $0.21. The company had revenue of $305.00 million for the quarter, compared to the consensus estimate of $298.90 million. During the same quarter last year, the company posted $0.17 earnings per share. Amedisys’s revenue was down 3.5% compared to the same quarter last year. Analysts expect that Amedisys will post $0.07 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on AMED. Analysts at Credit Suisse reiterated an “underperform” rating on shares of Amedisys in a research note on Thursday. They now have a $17.00 price target on the stock, up previously from $9.00. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of Amedisys in a research note on Thursday. They now have a $22.00 price target on the stock, up previously from $14.00. Finally, analysts at Piper Jaffray raised their price target on shares of Amedisys from $12.00 to $18.00 in a research note on Thursday. They now have a “neutral” rating on the stock. Two investment analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $17.06.
Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.